Published in J Clin Hypertens (Greenwich) on April 01, 2004
Burden of Hypertension and Abnormal Glomerular Permeability in Hypertensive School Children. Nephrourol Mon (2016) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens (2003) 5.94
Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med (2002) 5.72
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens (2013) 4.28
Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension (2009) 3.93
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens (2008) 3.32
Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens (2005) 3.15
Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens (2009) 3.13
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens (2009) 2.68
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Added impact of obesity and insulin resistance in nocturnal blood pressure elevation in children and adolescents. Hypertension (2008) 2.31
ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens (2012) 2.24
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension (2012) 2.02
Carotid-femoral pulse wave velocity assessment by two different methods: implications for risk assessment. J Hypertens (2015) 1.98
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press (2009) 1.98
Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens (2007) 1.86
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation (2011) 1.77
Microvascular brain damage with aging and hypertension: pathophysiological consideration and clinical implications. J Hypertens (2011) 1.76
Blood pressure and obesity exert independent influences on pulse wave velocity in youth. Hypertension (2012) 1.70
Influence of concurrent obesity and low birth weight on blood pressure phenotype in youth. Hypertension (2009) 1.64
Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension (2005) 1.61
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens (2014) 1.58
Associations of birth weight and postnatal weight gain with cardiometabolic risk parameters at 5 years of age. Hypertension (2014) 1.52
Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. J Hypertens (2012) 1.49
2016 European Guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed) (2016) 1.42
Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment. J Hypertens (2013) 1.39
[Renal function as a prognostic marker of mortality in heart failure]. Med Clin (Barc) (2009) 1.38
Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int (2009) 1.16
Ultrafiltration and small solute transport at initiation of PD: questioning the paradigm of peritoneal function. Perit Dial Int (2005) 1.15
Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch (2004) 1.06
Birth weight impacts on wave reflections in children and adolescents. Hypertension (2002) 1.01
Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens (2013) 0.94
The impact of the degree of obesity on the discrepancies between office and ambulatory blood pressure values in youth. J Hypertens (2006) 0.93
Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens (2012) 0.93
What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention (2014) 0.92
Common variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. PLoS One (2012) 0.92
European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. J Hypertens (2009) 0.91
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol (2007) 0.90
Inadequate cytoplasmic antioxidant enzymes response contributes to the oxidative stress in human hypertension. Am J Hypertens (2007) 0.88
Xanthine oxidoreductase polymorphisms: influence in blood pressure and oxidative stress levels. Pharmacogenet Genomics (2007) 0.86
Renin polymorphisms and haplotypes are associated with blood pressure levels and hypertension risk in postmenopausal women. J Hypertens (2008) 0.86
Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study. J Hypertens (2006) 0.85
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens (2014) 0.85
Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population. Am J Hypertens (2009) 0.84
Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire. J Hypertens (2010) 0.84
New developments in the pathogenesis of obesity-induced hypertension. J Hypertens (2015) 0.84
2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens (2016) 0.83
Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention (2013) 0.83
Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. Eur J Prev Cardiol (2012) 0.83
Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens (2016) 0.83
Nocturnal blood pressure versus nondipping pattern: what do they mean? Hypertension (2007) 0.83
Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia. BMC Public Health (2010) 0.82
Polymorphisms of the UCP2 gene are associated with body fat distribution and risk of abdominal obesity in Spanish population. Eur J Clin Invest (2011) 0.82
Measurement of microalbuminuria--what the nephrologist should know. Nephrol Dial Transplant (2005) 0.81
Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension (2005) 0.81
Eating behavior disorders in uremia: a question of balance in appetite regulation. Semin Dial (2004) 0.81
The impact of birth weight on pulse pressure during adolescence. Blood Press Monit (2004) 0.81
Dietary polyunsaturated fatty acids may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers of an ABCG1 gene single nucleotide polymorphism: study in two Spanish populations. Atherosclerosis (2011) 0.80
Prevalence and factors related to urinary albumin excretion in obese youths. J Hypertens (2013) 0.79
[Practice guidelines 2007 for the treatment of arterial hypertension]. G Ital Cardiol (Rome) (2007) 0.79
The effects of telmisartan alone or with hydrochlorothiazide on morning and 24-h ambulatory BP control: results from a practice-based study (SURGE 2). Hypertens Res (2012) 0.79
Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients. Adv Perit Dial (2002) 0.79
Diagnosis and treatment of hypertension in children. Curr Hypertens Rep (2010) 0.79
Genetic bases of urinary albumin excretion and related traits in hypertension. J Hypertens (2010) 0.79
European Society of Hypertension Working Group on Obesity: background, aims and perspectives. J Hypertens (2007) 0.79
Malnutrition-inflammation syndrome is associated with endothelial dysfunction in peritoneal dialysis patients. Adv Perit Dial (2003) 0.79
Treatment of hypertension and the price to pay; adverse events and discontinuation from randomized treatment in clinical trials. J Hypertens (2016) 0.78
Different impacts of cardiovascular risk factors on oxidative stress. Int J Mol Sci (2011) 0.78
Increased oxidative stress levels and normal antioxidant enzyme activity in circulating mononuclear cells from patients of familial hypercholesterolemia. Metabolism (2009) 0.78
[Differences between office and ambulatory control of hypertension in very elderly patients. The CARDIORISC - MAPAPRES project]. Med Clin (Barc) (2009) 0.78
Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte-derived dendritic cells: effect of lactate and glucose-degradation products. J Leukoc Biol (2003) 0.78
Urinary albumin excretion: lowering the threshold of risk in hypertension. Hypertension (2005) 0.77
Impaired exercise tolerance is associated with increased urine albumin excretion in the early stages of essential hypertension. Eur J Prev Cardiol (2011) 0.77
Reproducibility and validity of ambulatory blood pressure monitoring in children. Am J Hypertens (2002) 0.77
Sexual dimorphism in the transition from masked to sustained hypertension in healthy youths. Hypertension (2013) 0.77
Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens (2002) 0.77
Gender differences related to the presence of atrial fibrillation in older hypertensive patients. World J Cardiol (2013) 0.77
Association of selected ABC gene family single nucleotide polymorphisms with postprandial lipoproteins: results from the population-based Hortega study. Atherosclerosis (2010) 0.77
Nocturnal hypertension: will control of nighttime blood pressure prevent progression of diabetic renal disease? Curr Hypertens Rep (2004) 0.77
Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. J Hypertens (2014) 0.76
Morning and smooth 24-h ambulatory blood pressure control is not achieved in general practice: results from the SURGE observational study. J Hypertens (2013) 0.76
Influence of obesity in central blood pressure. J Hypertens (2015) 0.76
Discordant response of glutathione and thioredoxin systems in human hypertension? Antioxid Redox Signal (2007) 0.76
Discrepancies in office and ambulatory blood pressure in adolescents: help or hindrance? Pediatr Nephrol (2007) 0.75
Necessity of add-on therapy in the treatment of hypertension: a new marker of high cardiovascular risk? J Hypertens (2012) 0.75
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.75
New insights into urinary proteins as markers of cardiovascular risk in hypertension. J Hypertens (2006) 0.75
Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord (2014) 0.75
Reply. J Hypertens (2015) 0.75